Literature DB >> 2477497

Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector.

M W Wathen1, R J Brideau, D R Thomsen, B R Murphy.   

Abstract

Human respiratory syncytial virus (RSV) codes for two glycoproteins (F and G) which have been shown to the major targets for the host antibody response. We have expressed a novel chimeric glycoprotein (FG) in insect cells using a baculovirus vector. The chimeric glycoprotein contains the signal and extracellular regions of the RSV F glycoprotein linked to the extracellular region of the RSV G glycoprotein. Beginning at the amino terminus, the chimeric glycoprotein consists of amino acids 1 to 489 from RSV F followed by amino acids 97 to 279 from RSV G. The chimeric FG glycoprotein did not contain an anchor region and was efficiently secreted into the medium of recombinant baculovirus-infected insect cells. The FG glycoprotein ranged in size from 69K to 91K and was heterogeneous with respect to isoelectric point. The cleavage site present on the F glycoprotein was recognized on the chimeric FG, and the glycoprotein appeared to be antigenically similar to the native RSV F and G glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477497     DOI: 10.1099/0022-1317-70-10-2625

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells.

Authors:  M Parrington; S Cockle; P Wyde; R P Du; E Snell; W Y Yan; Q Wang; L Gisonni; S Sanhueza; M Ewasyshyn; M Klein
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

2.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

Authors:  J A Nicholas; K L Rubino; M E Levely; E G Adams; P L Collins
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.

Authors:  M E Levely; C A Bannow; C W Smith; J A Nicholas
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.

Authors:  G A Prince; C Capiau; M Deschamps; L Fabry; N Garçon; D Gheysen; J P Prieels; G Thiry; O Van Opstal; D D Porter
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Immunological response of mice to the bovine respiratory syncytial virus fusion glycoprotein expressed in recombinant baculovirus infected insect cells.

Authors:  K Walravens; J P Matheise; I Knott; P Coppe; A Collard; C Didembourg; F Dessy; R Kettmann; J J Letesson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Authors:  C F Barbas; J E Crowe; D Cababa; T M Jones; S L Zebedee; B R Murphy; R M Chanock; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 8.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

9.  Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development.

Authors:  Rebecca J Loomis; Guillaume B E Stewart-Jones; Yaroslav Tsybovsky; Ria T Caringal; Kaitlyn M Morabito; Jason S McLellan; Amy L Chamberlain; Sean T Nugent; Geoffrey B Hutchinson; Lisa A Kueltzo; John R Mascola; Barney S Graham
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.